证券代码：688393 证券简称：安必平 公告编号：2025-043 广州安必平医药科技股份有限公司 关于自愿披露公司及子公司 2025 年 7-9 月获得 资质情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州安必平医药科技股份有限公司(以下简称"公司")及子公司在 2025 年 7-9 月获得国内医疗器械注册/备案证 36 项，获得知识产权类资质 6 项，获得 境外认证 6 项。相关信息如下： 一、获得资质的具体情况 | 序号 | 产品名称 | 证书编号 | 证书有效期 | 注册 | 所属技 | | --- | --- | --- | --- | --- | --- | | | | | | 分类 | 术平台 | | 1 | 人乳头瘤病毒核酸检测试剂盒 | 国械注准 | 2025.7- | Ⅲ | PCR | | | （实时荧光 PCR 法） | 20253401310 | 2030.7 | | | | 2 | PRAME 抗体试剂(免疫组织化 | 粤穗械备 | 2025.7-长期 | Ⅰ | IHC | ...

Report Industry Investment Rating There is no information provided regarding the report industry investment rating. Core Viewpoints of the Report Through macro - fundamental and technical analysis, the report predicts the trends of various futures contracts on September 26, 2025, and also gives the expected trends for September 2025. It also provides information on macro - news and trading alerts, and analyzes the performance of various futures contracts on September 25, 2025 [2][7][12]. Summary by Relevant Catalogs 1. Futures Market Forecast - **Stock Index Futures**: Expected to oscillate and consolidate. IF2512 has resistance at 4588 and 4600 points, support at 4550 and 4529 points; IH2512 has resistance at 2970 and 2981 points, support at 2946 and 2939 points; IC2512 has resistance at 7250 and 7300 points, support at 7139 and 7100 points; IM2512 has resistance at 7380 and 7459 points, support at 7245 and 7174 points [2]. - **Treasury Bond Futures**: The ten - year Treasury bond futures contract T2512 is likely to oscillate weakly, with support at 107.40 and 107.30 yuan, resistance at 107.72 and 107.83 yuan. The thirty - year Treasury bond futures contract TL2512 is likely to oscillate weakly in a wide range, with support at 113.5 and 113.0 yuan, resistance at 114.3 and 114.7 yuan [2]. - **Precious Metal Futures**: Gold futures contract AU2512 is likely to oscillate strongly, with resistance at 862.1 and 865.0 yuan/gram, support at 850.0 and 848.0 yuan/gram. Silver futures contract AG2512 is likely to oscillate strongly and will attack the resistance at 10600 and 10680 yuan/kg, support at 10411 and 10397 yuan/kg, and may hit a new high since listing [3]. - **Base Metal Futures**: Copper futures contract CU2511 is likely to oscillate in a wide range and will accumulate strength to attack the resistance at 83300 and 84000 yuan/ton, support at 82000 and 81500 yuan/ton. Aluminum futures contract AL2511 is likely to oscillate strongly and will attack the resistance at 20860 and 20940 yuan/ton, support at 20740 and 20700 yuan/ton. Alumina futures contract AO2601 is likely to oscillate weakly and will test the support at 2900 and 2877 yuan/ton, resistance at 2942 and 2960 yuan/ton [3]. - **Other Commodity Futures**: Crude oil futures contract SC2511 is likely to oscillate and consolidate, with resistance at 492 and 494 yuan/barrel, support at 485 and 483 yuan/barrel. Fuel oil futures contract FU2601 is likely to oscillate strongly, with resistance at 2910 and 2929 yuan/ton, support at 2887 and 2873 yuan/ton. PTA futures contract TA601, PVC futures contract V2601, and bean meal futures contract M2601 are likely to oscillate weakly. Natural rubber futures contract RU2601 is likely to oscillate weakly and will test the support at 15210 and 15110 yuan/ton [6]. 2. Macro - news and Trading Alerts - The Ministry of Commerce took multiple measures, including adding US entities to export - control and unreliable - entity lists, responding to Sino - US soybean trade issues, initiating trade - investment barrier investigations against Mexico, and launching an anti - dumping investigation into imported pecans from Mexico and the US [7]. - The digital RMB international operation center was officially launched, and the tax department and platforms are preparing for the first tax - related information submission. The US Q2 GDP growth was revised upwards, and some Fed officials advocated for interest - rate cuts [8]. 3. Futures Market Analysis and Forecast - **Stock Index Futures**: On September 25, 2025, IF2512, IH2512, and IC2512 showed different degrees of upward movement, while IM2512 showed a slight decline. The report also gives the expected trends for September 2025, all contracts are likely to oscillate in a wide range [12][13][16]. - **Treasury Bond Futures**: On September 25, 2025, the ten - year Treasury bond futures contract T2512 oscillated weakly, and the thirty - year Treasury bond futures contract TL2512 oscillated slightly upwards. The report gives the expected trends for September 26, 2025 [37][40]. - **Precious Metal Futures**: On September 25, 2025, the gold futures contract AU2512 oscillated downwards, and the silver futures contract AG2512 oscillated upwards and hit a new high during the night session. The report gives the expected trends for September 2025 and September 26, 2025 [45][50]. - **Base Metal Futures**: On September 25, 2025, copper, aluminum, and other base metal futures showed different trends. The report gives the expected trends for September 2025 and September 26, 2025 [56][61]. - **Other Commodity Futures**: On September 25, 2025, various commodity futures such as crude oil, fuel oil, and PTA showed different trends. The report gives the expected trends for September 2025 and September 26, 2025 [100][104][111].

Industry Overview - The fully automatic staining and mounting machine integrates automated staining and mounting functions, primarily used in the field of pathological diagnosis. It significantly enhances laboratory efficiency and consistency of results while reducing human error [3][4] - The machines are categorized into two types: online machines for high-volume processing in major hospitals and standalone machines for smaller medical institutions [3] Industry Value Chain - The industry value chain consists of three segments: upstream supply of core components and consumables, midstream manufacturing, and downstream application in hospitals, clinics, and research institutions. Hospitals account for over 60% of the demand [4] - The fully automatic staining and mounting machine belongs to the in vitro diagnostics (IVD) sector, which is projected to reach a market size of approximately 120 billion yuan in 2024, growing at 1.27% year-on-year [4] Market Size Analysis - The market for fully automatic staining and mounting machines is expected to grow from approximately 1.53 billion yuan in 2019 to 1.77 billion yuan in 2024, with a compound annual growth rate (CAGR) of over 2.5% [5] - Global market size is projected to reach approximately 215 million USD in 2024, with a CAGR of 6.5%, potentially reaching 332 million USD by 2031 [5] Competitive Landscape - The Chinese market is characterized by domestic dominance, foreign technological leadership, and regional competition. Key players include Ningbo Chaw Microbiology Technology, Shandong Enzhong Medical Technology, and Anbiping [7][8] - Ningbo Chaw has developed the first domestic automatic mounting machine, achieving speeds of 720 slides/hour for staining and 800 slides/hour for mounting, with a presence in 48% of the top 100 hospitals in China [7] Industry Development Trends - The industry is moving towards smart and integrated upgrades, incorporating AI and IoT technologies for sample recognition and process automation [9] - There is a focus on high throughput and efficiency, with ongoing hardware design optimizations to increase sample capacity and processing speed [9] - Companies are shifting from equipment sales to a service-oriented model, offering data analysis and remote training, while also pursuing energy-efficient solutions [9]

Core Viewpoint - Anbiping's stock price has shown significant volatility in 2023, with a year-to-date increase of 57.23%, but recent declines in the short term raise concerns about its performance [2]. Financial Performance - As of June 30, 2025, Anbiping reported a revenue of 159 million yuan, a year-on-year decrease of 30.11%, and a net profit attributable to shareholders of -12.5 million yuan, a decline of 176.38% [2]. - The company has distributed a total of 87.8 million yuan in dividends since its A-share listing, with 36.5 million yuan distributed over the past three years [3]. Stock Market Activity - On September 25, Anbiping's stock rose by 2.04% to 27.06 yuan per share, with a trading volume of 16.5 million yuan and a turnover rate of 0.66%, resulting in a total market capitalization of 2.532 billion yuan [1]. - The stock has experienced a net outflow of 844,700 yuan in principal funds, with large orders accounting for 18.17% of total purchases and 23.29% of total sales [1]. Shareholder Structure - As of June 30, 2025, Anbiping had 9,221 shareholders, a decrease of 10.55% from the previous period, with an average of 10,147 circulating shares per shareholder, an increase of 11.80% [2]. - Among the top ten circulating shareholders, Changcheng Consumption Value Mixed A (200006) is the eighth largest, holding 850,000 shares as a new shareholder [3]. Business Overview - Anbiping, established on July 6, 2005, and listed on August 20, 2020, is based in Guangzhou, Guangdong Province, and specializes in the research, production, and sales of in vitro diagnostic reagents and instruments [2]. - The company's revenue composition includes 79.72% from self-produced products, 13.11% from purchased products, 5.90% from service income, and 1.27% from other sources [2].

Core Viewpoint - Anbiping's stock price has experienced fluctuations, with a year-to-date increase of 57% but a recent decline in the last 5 and 20 trading days, indicating potential volatility in investor sentiment and market performance [2]. Financial Performance - As of June 30, 2025, Anbiping reported a revenue of 159 million yuan, a year-on-year decrease of 30.11%, and a net profit attributable to shareholders of -12.5 million yuan, a significant decline of 176.38% [2]. - The company has distributed a total of 87.8 million yuan in dividends since its A-share listing, with 36.5 million yuan distributed over the past three years [3]. Stock Market Activity - On September 19, Anbiping's stock price fell by 2.03% to 27.02 yuan per share, with a trading volume of approximately 23.9 million yuan and a turnover rate of 0.94%, resulting in a total market capitalization of 2.528 billion yuan [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent appearance on February 17, where it recorded a net buy of -6.86 million yuan [2]. Shareholder Information - As of June 30, 2025, Anbiping had 9,221 shareholders, a decrease of 10.55% from the previous period, with an average of 10,147 circulating shares per shareholder, an increase of 11.80% [2]. - Among the top ten circulating shareholders, Changcheng Consumption Value Mixed A (200006) is the eighth largest, holding 850,000 shares as a new shareholder [3]. Business Overview - Anbiping, established on July 6, 2005, and listed on August 20, 2020, is based in Guangzhou, Guangdong Province, and specializes in the research, production, and sales of in vitro diagnostic reagents and instruments [2]. - The company's revenue composition includes 79.72% from self-produced products, 13.11% from purchased products, 5.90% from service income, and 1.27% from other sources [2].

Core Points - Anbiping (688393.SH) reported a significant decline in revenue and net profit for the first half of 2025, with revenue at 159 million yuan, down 30.11% year-on-year, and a net profit attributable to shareholders of -12.5 million yuan compared to a profit of 16.4 million yuan in the same period last year [1] - The company has experienced a continuous decline in net profit for four consecutive years, with net profits of 84.7 million yuan in 2020, decreasing to 21.3 million yuan in 2024 [1] - Anbiping was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 20, 2020, with an initial issuance of 23.34 million shares at a price of 30.56 yuan per share [1] Financial Performance - For the first half of 2025, Anbiping's net profit excluding non-recurring gains and losses was -14.7 million yuan, down from 10.5 million yuan in the previous year [1] - The company's operating cash flow improved to 19.0 million yuan, compared to -11.3 million yuan in the same period last year [1] - Historical net profits from 2020 to 2024 show a downward trend, with figures of 84.7 million yuan, 79.8 million yuan, 42.7 million yuan, 40.1 million yuan, and 21.3 million yuan respectively [1] IPO and Stock Performance - Anbiping's initial public offering raised a total of 713 million yuan, with a net amount of 640 million yuan after deducting issuance costs, exceeding the original plan by 266 million yuan [2] - The company’s stock reached a peak price of 74.00 yuan on its first trading day but is currently in a state of decline [2] - The funds raised were intended for the construction of a research and production base and the upgrade of the marketing service network [2]

Core Points - Anbiping announced the convening of its first extraordinary general meeting of shareholders for 2025 on September 9, 2025 [2] - The meeting approved the proposal to temporarily adjust the use of idle sites for certain fundraising investment projects [2] Summary by Category - **Company Announcement** - Anbiping will hold its first extraordinary general meeting of shareholders for 2025 on September 9, 2025 [2] - **Investment Project Adjustments** - The shareholders' meeting approved a proposal to temporarily adjust the use of idle sites related to certain fundraising investment projects [2]

证券代码：688393 证券简称：安必平 公告编号：2025-042 广州安必平医药科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 9 日 （二） 股东大会召开的地点：广州市黄埔区科信街 2 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 38 | | --- | --- | | 普通股股东人数 | 38 | | 2、出席会议的股东所持有的表决权数量 | 33,600,596 | | 普通股股东所持有表决权数量 | 33,600,596 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 35.9105 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 35.9105 | （四） 表决方式是否 ...

股东大会法律意见书 達律師事務所 INDIAL LAW FIRM 中国深圳市福田区益田路 6001 号太平金融大厦 11、12 楼 邮编: 518038 11-12/F, TAIPING FINANCE TOWER, YITIAN ROAD 6001, FUTIAN DISTRICT, SHENZHEN, P.R. CHINA 电话(Tel):(0755)88265288 传真(Fax):(0755)88265537 电子邮件(E-mail): info@sundiallawfirm.com 网址(Website): www.sundiallawfirm.com 广东信达律师事务所 关于广州安必平医药科技股份有限公司 2025 年第一次临时股东大会的法律意见书 信达科会字(2025)第 042 号 1 國國信達律師事務所 股东大会法律意见书 意见书出具日以前已经发生或者存在的事实,严格履行了法定职责,遵循了勤勉 尽责和诚实信用原则,进行了充分的核查验证,保证本法律意见书所认定的事实 真实、准确、完整,所发表的结论性意见合法、准确,不存在虚假记载、误导性 陈述或者重大遗漏,并承担相应法律责任。 本法律意见书仅供 ...

广州安必平医药科技股份有限公司 2025 年第一次临时股东大会会议资料 公司代码：688393 公司简称：安必平 广州安必平医药科技股份有限公司 2025 年第一次临时股东大会 会议资料 2025 年 9 月 广州安必平医药科技股份有限公司 2025 年第一次临时股东大会会议资料 目录 | 2025 | 年第一次临时股东大会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议议程 | 4 | | 2025 | 年第一次临时股东大会会议议案 | 6 | | | 议案一 关于暂时调整部分募集资金投资项目闲置场地用途的议案 | 6 | 1 广州安必平医药科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》以及《广州安必平医药科技股份有限公司章程》《广州安 必平医药科技股份有限公司股东大会议事规则》等相关规定，特制定本次股东大 会会议须知： 一、为保证股东大会的 ...